Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 11/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207324 | 1.00 | MELK (0.45) | MELKHRH3ACP1TAAR1CYP17A1 | |
| SCHEMBL23630646 | 0.87 | HRH3 (0.46) | MELKHRH3ACP1TAAR1CYP17A1 | |
| SCHEMBL31207322 | 0.87 | HRH3 (0.46) | MELKHRH3ACP1TAAR1CYP17A1 | |
| SCHEMBL23630637 | 0.80 | HRH3 (0.47) | MELKHRH3ACP1TAAR1HTR7 | |
| SCHEMBL31207326 | 0.80 | HRH3 (0.47) | MELKHRH3ACP1TAAR1HTR7 | |
| SCHEMBL23630647 | 0.78 | ACP1 (0.47) | MELKHRH3ACP1TAAR1 | |
| SCHEMBL31207320 | 0.78 | ACP1 (0.47) | MELKHRH3ACP1TAAR1 | |
| SCHEMBL21589940 | 0.74 | ACP1 (0.47) | MELKHRH3ACP1TAAR1 | |
| SCHEMBL23630643 | 0.72 | MAOB (0.54) | HRH3ACP1TAAR1 | |
| SCHEMBL29922075 | 0.72 | MAOB (0.54) | HRH3ACP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | claimed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | claimed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | claimed |
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | MELK 852/4885HRH3 3017/4885ACP1 729/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | MELK 852/4885HRH3 3017/4885ACP1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.